{"filings":[{"id":2503201,"accession_number":"0001493152-26-040329","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2026-08-27T12:30:22+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Interpace Biosciences announces 1-for-5 reverse stock split to support Nasdaq uplisting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-5 reverse stock split effective 12:01 a.m. ET Aug 27, 2026; shares reduced from ~27.7M to ~5.5M.","Ticker temporarily changes to IDXGD for 20 trading days; new CUSIP 46062X402; par value unchanged at $0.01.","Split intended to meet Nasdaq minimum bid price requirement; company also needs $15M market value of unrestricted public shares.","Proportional adjustments to outstanding stock options, RSUs, and equity plan shares; fractional shares rounded up.","CEO Tom Burnell: split is key part of strategy to uplist to Nasdaq and attract broader investor base."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2480356,"accession_number":"0001493152-26-040182","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K/A","filed_at":"2026-08-26T14:45:11+00:00","items":["5.02","9.01"],"status":"ready","headline":"Interpace Biosciences stockholders approve 2026 equity incentive plan and ESPP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 2026 Equity Incentive Plan and 2026 ESPP at Aug 20, 2026 annual meeting.","New plans replace 2019 Equity Incentive Plan and 2019 ESPP; no further grants or purchases under old plans.","Material terms previously disclosed in proxy statement filed July 7, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2391041,"accession_number":"0001493152-26-039530","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2026-08-20T22:45:15+00:00","items":["5.07"],"status":"ready","headline":"Interpace shareholders approve reverse split up to 1-for-10, equity plans, and director slate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split authorized (1:2 to 1:10 ratio, board discretion within 1 yr): 26,180,980 for, 397,262 against.","Amended & restated certificate of incorporation approved: 24,981,181 for, 246,552 against, 3,625 abstain.","All five director nominees elected, incl. CEO Thomas W. Burnell (25,095,783 for) and Joseph D. Keegan (24,422,783 for).","2026 Equity Incentive Plan approved: 24,887,762 for; 2026 Employee Stock Purchase Plan: 24,580,773 for.","Say-on-pay passed (24,952,970 for); EisnerAmper LLP ratified as auditor (26,442,760 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2217117,"accession_number":"0001493152-26-037360","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2026-08-12T20:15:20+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Q2 2026: revenue $9.1M, income $0.3M vs prior loss; thyroid revenue +9% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $9.1M, up 9% Pro Forma (ex-PancraGEN); income from continuing ops $0.3M vs $0.5M loss prior year.","Thyroid revenue +9% YoY, volume +6%; TTM thyroid revenue $36.1M, up 11%; gross margin 62% vs 54% Pro Forma.","Adjusted EBITDA $0.7M (8% margin) vs $0.2M Pro Forma prior year; includes $0.2M one-time strategic fees.","H1 2026 income $1.1M vs $0.2M loss Pro Forma; Adjusted EBITDA $2.3M (13% margin); debt-free balance sheet.","Adding Chief Scientific Officer Sept 8, 2026; pancreatic cancer program in development, no revenue expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":18163000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442969,"accession_number":"0001493152-26-023095","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2026-05-14T20:15:44+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Biosciences Q1 2026 revenue $9.0M, thyroid revenue up 12% YoY; reaffirms 16% growth guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $9.0M; GAAP down 22% YoY due to PancraGEN exit, but Pro Forma revenue up 14% to $9.0M from $7.9M.","Adjusted EBITDA $1.6M (17% margin) vs $0.8M Pro Forma in prior year; operating income margin improved to 12% from 6% Pro Forma.","Thyroid test volume increased 10% YoY; revenue per test up 3%; active accounts increased 5%.","Gross margin expanded to 65% from 59% Pro Forma; company debt-free with $8.7M cash collections in Q1.","Reaffirmed 2026 guidance of ~16% year-over-year thyroid revenue growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":9032000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90946,"accession_number":"0001493152-26-014654","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Q4 revenue $9.2M, thyroid revenue +14% YoY; debt fully paid off","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $9.2M, FY revenue $38.7M; Q4 income from cont. ops $22.8M (includes one-time tax adjustment).","Thyroid revenue +14% YoY in Q4, +21% for FY; thyroid volume +11% Q4, +13% FY.","Debt fully paid off in Q4 2025; cash availability up $4.3M YoY.","Adjusted EBITDA Q4 $1.7M, FY $5.4M; company reiterates ~16% thyroid revenue growth guidance for 2026.","Business metrics improved: avg revenue/test +5%, DSO -19%, turnaround time -20%, accounts +9%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":9032000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100808,"accession_number":"0001493152-26-002772","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Guidance, and Preferred Stock Conversion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary 2025 thyroid testing revenue of ~$34-35M, up 21% over prior year.","Company initiates 2026 revenue guidance of ~$40M, representing 16% growth in thyroid testing.","All outstanding Series C Preferred Stock converted into common stock at $2.02 per share, issuing ~23.3M shares.","Company is debt-free with positive net income and EBITDA, plans to seek uplisting to Nasdaq in 2026.","Following conversion, pro forma basic shares outstanding ~27.7M; 1315 Capital owns ~34%, Ampersand owns ~50%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117111,"accession_number":"0001493152-25-025960","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Interpace Biosciences fully repays BroadOak term loan early, strengthens balance sheet","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fully repaid outstanding term loan facility with BroadOak Capital Partners prior to maturity.","Original Loan and Security Agreement dated October 29, 2021 with BroadOak Fund V, L.P.","Early repayment eliminates related interest expenses, increasing operational flexibility.","CFO Chris McCarthy says repayment reflects robust financial performance and disciplined capital management.","Company now focused on driving commercial growth and record testing volumes/revenue for thyroid tests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117110,"accession_number":"0001493152-25-021980","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Biosciences Reports Q3 2025 Revenue of $8.8M, Thyroid Test Volume Up 12% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenue $8.8M, up 22% pro forma vs prior year; operating income $1.1M","Thyroid test volume grew 12% year-over-year to record levels; thyroid revenue $8.8M, up 22%","Cash collections $10.0M in Q3; days sales outstanding reduced 22%","Income from continuing operations $1.0M; adjusted EBITDA $1.3M","Company completed transition to thyroid-only diagnostics; additional debt principal payments made"],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":29504000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133561,"accession_number":"0001641172-25-022774","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Biosciences Q2 revenue down 23% to $9.2M; loss from continuing ops $0.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $9.2M (-23% YoY); loss from continuing ops $0.5M vs income $2.5M a year ago.","Thyroid test volume up 16% YoY; thyroid revenue $8.7M (+25% YoY) to record levels.","Gross margin 57% (65% ex one-time PancraGEN impact); adjusted EBITDA $0.4M vs $2.8M.","One-time charge $1.2M from PancraGEN reimbursement loss; company winding down test.","Preliminary July 2025 revenue $3.3M (+54% YoY); management sees Q3 improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":20747000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150235,"accession_number":"0001641172-25-009273","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Q1 revenue $11.5M (+13% YoY); guides FY2025 ~$38M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $11.5M (+13% YoY); income from continuing ops $1.8M vs $0.8M.","Thyroid revenue $8.0M (+19% YoY) to record; test volume up 16%.","Cash collections $11.3M (+10% YoY) to record; adjusted EBITDA $2.1M vs $1.2M.","Initiates FY2025 revenue guidance of approx. $38M despite PancraGEN loss after May 2.","Gross profit margin improved to 64% from 62%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":11515000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150234,"accession_number":"0001641172-25-007944","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.05","8.01","9.01"],"status":"ready","headline":"Interpace Biosciences restructures after Medicare LCD ends PancraGEN coverage","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Medicare LCD L39365 ends PancraGEN reimbursement as of April 24, 2025; no specimens after May 2.","Workforce reduction announced; severance costs $0.5-0.6M in Q2 plus $0.2M in Q1 2025.","Restructuring to cut annual cost of revenue and OpEx by $12.5-14.5M, offsetting ~1/3 of revenue loss.","Plan substantially complete by end of Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169244,"accession_number":"0001493152-25-009384","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Interpace Biosciences to restate 2023 and quarterly 2023/2024 financials due to accrued royalty errors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Accrued royalties overstated by $5.3M to $7.1M across 2023 and 2024 quarterly balance sheets.","Restatement expected to reduce liabilities and increase net income; revenues and cash flows unchanged.","Non-reliance on financial statements for FY2023, Q1-Q3 2023 and Q1-Q3 2024.","Management will report a material weakness in internal controls over accrued royalty assessment.","Cumulative impact from 2015-2022 is $4.8M aggregate; no restatement for periods before 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169243,"accession_number":"0001493152-25-003797","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["2.05","8.01","9.01"],"status":"ready","headline":"Interpace Biosciences: CMS delays Genetic Testing LCD to April 24, 2025; Company re-evaluates restructuring plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS directed Medicare contractors to delay implementation of LCD L39365 from Feb 23 to April 24, 2025.","Delay allows Trump administration to review clinical evidence for PancraGEN assay and assess patient impact.","Interpace will continue offering PancraGEN and re-evaluate its previously announced restructuring plan.","CEO Burnell stated the company is sustainable without PancraGEN but extension preserves jobs and patient access.","PancraGEN has been covered by Medicare for over 10 years, helped over 80,000 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169242,"accession_number":"0001493152-25-003019","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["1.01","2.03","2.05"],"status":"ready","headline":"Interpace restructures debt and cuts workforce after CMS drops PancraGEN coverage","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fourth Amendment: monthly $500k principal payments Feb-Jun 2025, interest-only Jul-Dec, final balance due Dec 31, 2025; 1% restructuring fee paid on Jan 17, 2025.","Board approved restructuring plan Jan 14, 2025 due to CMS ending PancraGEN coverage (announced Jan 9, 2025).","Workforce reduction; severance costs estimated $0.8M–$1.0M, primarily recorded in Q1 2025.","Expected annual cost savings of $12.5M–$14.5M, expected to offset approximately one-third of revenue loss from PancraGEN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169241,"accession_number":"0001493152-25-001699","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CMS final LCD denies coverage for Interpace's PancraGEN test; company to discontinue after Feb 7, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS issued final LCD L39365 establishing non-coverage for PancraGEN, a DNA-based test assessing pancreatic cyst cancer risk.","Interpace will stop accepting PancraGEN specimens after February 7, 2025; test primarily ordered for Medicare patients.","PancraGEN has helped over 80,000 patients since 2013; CEO calls decision inconsistent with advancing patient care.","Company plans restructuring but expects to remain profitable with ThyGeNEXT + ThyraMIR v2 thyroid tests.","Interpace will consider all remedies against CMS/Novitas regarding the non-coverage decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186283,"accession_number":"0001493152-24-045132","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders ratify appointment of EisnerAmper as auditor for FY2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Over 10.97M shares voted FOR ratification, 13,711 against, 2,680 abstained.","Ratification passed with overwhelming majority; no broker non-votes.","Only item voted on at 2024 annual meeting held November 12, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186282,"accession_number":"0001493152-24-043851","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Biosciences Q3 revenue $12.3M, record test volume, swings to profit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenue $12.3M, up 35% YoY ($9.1M); test volume up 26% to record levels.","Operating income $1.9M vs operating loss of $0.02M a year ago; adjusted EBITDA $2.1M vs $0.4M.","Income from continuing ops $1.4M vs loss of $0.5M; gross margin 61% up from 55%.","Cash collections $11.3M (+15% YoY); cash $2.1M after $6.6M debt paydown; 18th consecutive quarter of YoY volume growth.","Company interviewing equity research partners and investment bankers for capital raise and potential Nasdaq listing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":34610000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186281,"accession_number":"0001493152-24-041144","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","7.01","9.01"],"status":"ready","headline":"Interpace exchanges all Series B Preferred for Series C Preferred; first step toward Nasdaq uplisting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 47,000 Series B Preferred shares (28,000 Ampersand, 19,000 1315 Capital) exchanged for Series C at $1,000 stated value.","Series C converts at $2.02/share (date closing price), no liquidation preference, no director designation rights, limited protective provisions.","Series C automatically converts to common upon Nasdaq uplisting; company believes Series C qualifies as stockholders' equity under GAAP.","Amended investor rights agreement provides registration rights; prior support agreement with 1315 Capital terminated.","Exchange is first step toward Nasdaq uplisting; no cash received; additional listing requirements may need to be satisfied."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202905,"accession_number":"0001493152-24-030102","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Q2 revenue $12.0M (+9% YoY); operating income $2.2M vs $0.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Test volume up 12% YoY to record levels; sixteenth consecutive quarter of YoY volume growth.","Operating income $2.2M vs $0.8M in prior-year quarter; income from continuing ops $2.1M vs $0.4M.","Adjusted EBITDA $2.3M vs $1.3M; cash collections $11.0M (+7% YoY).","Cash balance $2.0M at June 30, 2024, down from $5.1M due to $4.6M additional long-term debt paydown.","Gross profit margin stable at 62%; operating expenses down ~14% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":22314000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219103,"accession_number":"0001493152-24-018465","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Q1 revenue $10.3M (+4% YoY); income from ops $0.6M; record test volume +10%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenue $10.3M, up 4% YoY from $9.8M; test volume up 10% to record levels.","Income from continuing ops $0.6M vs $0.4M prior year; operating income $0.9M vs $0.7M.","Adjusted EBITDA $1.0M vs $1.2M prior year; gross margin 59% vs 61%.","Cash collections $10.2M; cash balance $2.8M at Mar 31, 2024, down from $5.6M due to $3.1M debt paydown.","Fifteenth consecutive quarter of YoY volume growth; CEO cites adoption of ThyGeNEXT, ThyraMIRv2, PancraGEN."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":10273000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238986,"accession_number":"0001493152-24-009737","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Biosciences reports record FY2023 revenue $40.2M (+26% YoY), swings to profit of $1.1M.","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $10.3M (+23% YoY); Q4 income from cont. ops $0.8M vs loss of $1.4M in prior year.","FY2023 adjusted EBITDA $4.5M (net of one-time charges) vs -$1.2M in 2022, a 463% reported improvement.","Cash collections for FY2023 $40.4M (+29% YoY); cash balance at Dec 31, 2023 was $3.5M.","Dr. Nicole Massoll appointed Chief Medical Officer effective March 2024.","10-K expected week of March 19, 2024; preliminary results subject to final audit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256473,"accession_number":"0001493152-23-044550","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Robert Gorman resigns from Interpace board, cites compensation dispute","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Gorman resigned as director and Chairman effective December 7, 2023.","Resignation not due to any disagreement with company's operations, policies, or practices.","Gorman disagreed with timing of proposed change from Executive Chairman to Chairman and reduction in compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256472,"accession_number":"0001493152-23-041662","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Director Edward Chan resigns from Interpace board; annual meeting results filed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Edward Chan resigned as Class II director effective Nov 15, 2023, not due to any disagreement.","Annual meeting held Nov 14, 2023; stockholders elected Thomas W. Burnell and Joseph Keegan as Class III directors.","Non-binding advisory vote on executive compensation approved with 9,177,922 for, 73,760 against.","Ratification of EisnerAmper LLP as auditor for FY 2023 approved with 10,907,312 for, 42,734 against.","Advisory vote on frequency of compensation votes: 9,089,392 voted for every three years (the board's recommendation)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256471,"accession_number":"0001493152-23-039945","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Biosciences Q3 revenue $9.1M (+11% YoY); expects FY2023 revenue >$40M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenue $9.1M, up 11% from $8.2M; test volume up 11% YoY.","Loss from continuing ops $(0.5)M vs $(1.3)M; adjusted EBITDA $0.4M vs $0.1M.","Repaid $2.5M Comerica line of credit and $3M Terminal Payment to BroadOak; renegotiated long-term debt.","Cash balance $5.0M at Sept 30, 2023; cash collections $9.8M vs $7.6M.","Expects full-year 2023 revenue to exceed $40M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":29931000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256470,"accession_number":"0001493152-23-038510","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Interpace Biosciences amends BroadOak loan: $2.5M lump sum to satisfy $3M terminal payment, rate cut to 8%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Lump sum payment of $2.5M due by Oct 31, 2023 in full satisfaction of $3M terminal payment under the Loan and Security Agreement.","Interest rate reduced from 9% to 8% per annum from Nov 1, 2023 through Oct 31, 2024.","Company may request extension of maturity date (Oct 31, 2024) with lender's sole discretion; 60-day notice required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273870,"accession_number":"0001493152-23-027331","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Q2 revenue $11.0M (+49% YoY); net income $0.4M vs loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $11.0M, up 49% YoY; gross margin improved to 62% from 52%.","Income from continuing operations $0.4M vs loss of $2.1M in Q2 2022.","Adjusted EBITDA $1.3M vs $(1.6)M loss; cash collections $10.2M, up 23% YoY.","Test volume up 15% YoY; cash balance increased to $5.1M from $1.9M.","Company faces Novitas LCD challenge for PancraGEN test; expects resolution in months to year."],"consensus_eps_estimate":null,"consensus_eps_actual":0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":20853000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273869,"accession_number":"0001493152-23-026343","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Interpace Biosciences appoints Christopher McCarthy as CFO effective July 24, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["McCarthy previously served as Principal Financial Officer since April 2023; base salary set at $220,000.","Eligible for annual bonus target up to 40% of base salary; received RSU grant of 25,000 shares (12,500 vested immediately, remainder in 6 months).","Additional 25,000 RSUs to be granted on July 27, 2024, fully vested on grant date.","Severance of 6 months base salary plus COBRA premiums for 6 months upon termination without cause or for good reason, subject to release.","Employment is at-will; no family relationships or related party transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290956,"accession_number":"0001493152-23-016686","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Biosciences Q1 2023 revenue $9.8M, up 24% YoY; turns profitable","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $9.8M (+24% YoY); test volume up ~20% to record levels.","Income from continuing ops $0.4M vs loss of $1.1M; operating income $0.7M vs loss $1.0M.","Adjusted EBITDA $1.2M vs -$0.3M; cash balance $5.6M vs $2.9M a year ago.","Added 41.9M covered lives via 8 new/updated commercial contracts in Q1.","Gross profit margin improved to 61% from 59% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":9826000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290955,"accession_number":"0001493152-23-013426","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2023-04-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Interpace Biosciences appoints Christopher McCarthy as Principal Financial Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher McCarthy, 31, appointed Principal Financial Officer effective April 21, 2023.","McCarthy had served as VP of Finance and Enterprise Systems since August 2022.","Prior roles at Interpace: Senior Director of Operations Finance (Aug 2020-Aug 2022) and Senior Financial Analyst (June 2019-Aug 2020).","Before Interpace, he was Senior Financial Systems Analyst at Simon & Schuster (Jan 2016-June 2019).","No family relationships or related party transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311794,"accession_number":"0001493152-23-009109","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Biosciences Q4 revenue $8.3M (-9% YoY); FY revenue $31.8M (-4%); loss narrows","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net revenue $8.3M, down 9% from $9.1M; operating income $0.1M vs loss of $1.4M prior year.","Full year net revenue $31.8M, down 4% due to ThyGeNEXT reimbursement decline ($3.6M impact).","Full year loss from continuing ops improved to $(5.9)M from $(7.0)M; adjusted EBITDA $(1.2)M vs $(2.0)M.","Cash balance $4.8M at Dec 31, 2022, up from $2.9M at Dec 31, 2021.","Management cites expense reductions and volume growth partially offsetting price headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330353,"accession_number":"0001493152-22-032503","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2022-11-15T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Interpace stockholders approve equity plan share increases and reverse split authorization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2019 Equity Incentive Plan, increasing authorized shares by 1,000,000 to total 2,230,000.","Stockholders approved amendment to Employee Stock Purchase Plan, increasing authorized shares by 1,000,000 to total 2,000,000.","Stockholders granted board discretionary authority to effect a reverse stock split within range of 1-for-2 to 1-for-10, within one year.","Stephen J. Sullivan elected as Class I director, receiving 8,793,313 votes for and 820,085 withhold.","Ratification of EisnerAmper LLP as independent auditor for fiscal year ending Dec 31, 2022 approved with 11,041,434 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330352,"accession_number":"0001493152-22-032187","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Q3 revenue $8.2M (+2%), adjusted EBITDA positive; going concern removed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $8.2M, up 2% YoY; gross margin improved to 58% from 55%.","Adjusted EBITDA positive $0.1M vs -$0.2M prior year; loss from continuing ops $1.3M.","Cash balance $6.3M (up from $3.2M); sale of Pharma business removed going concern.","ThyGeNEXT pricing change reduced revenue and EBITDA by ~$1.4M in Q3.","Nine-month revenue $23.5M (-2%); loss from continuing ops improved to -$4.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":5678000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330351,"accession_number":"0001493152-22-030690","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2022-11-04T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Interpace Biosciences extends Pittsburgh lab lease to June 2028 with $550k annual rent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fourth amendment to existing lease extends term through June 30, 2028.","Minimum annual rent $550,000 for the extended term.","Conditional tenant improvement credit of $200,000 if renovations exceed $250,000 by July 31, 2024.","Right of first refusal for an additional 4,632 leasable square feet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":330350,"accession_number":"0001493152-22-027554","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2022-10-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Interpace Biosciences CFO Thomas Freeburg resigns; continues as consultant and principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Thomas Freeburg resigned effective Sept 30, 2022; will serve as consultant and acting principal financial officer until new CFO hired.","Severance of $127,500 (six months' base salary) payable over six months; equity awards scheduled to vest in 24 months fully accelerated.","Consulting fee of $6,000/month for up to 20% time (~8 hrs/week); term from Sept 30, 2022 to Jan 30–Mar 30, 2023.","Health and dental benefits continued for six months at Company expense; COBRA eligibility if elected.","Company actively recruiting a replacement CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347910,"accession_number":"0001493152-22-025265","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2022-09-07T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"Interpace sells Pharma Services unit to Flagship for $7M; expects ~$5M annual cash flow improvement","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold Pharma Solutions business to Flagship Biosciences for ~$7M cash at close (plus up to $2M earnout based on revenue).","Transaction improves operating cash flow by nearly $5M annually, per CEO.","Pro forma: six-month 2022 operating loss narrows from $5.8M to $2.9M after sale.","Company becomes focused molecular diagnostics firm (PancraGEN, ThyGeNEXT, ThyraMIR, RespriDX, BarreGEN).","Ampersand and BroadOak affiliates provided equity to Flagship; Ampersand holds ~4.7M shares of Interpace common via Series B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347909,"accession_number":"0001493152-22-022992","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Q2 revenue $9.4M (-16% YoY), net loss $3.9M on ThyGeNEXT price cut","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $9.4M, down 16% YoY; net loss $3.9M vs $3.4M prior year.","Adjusted EBITDA $(2.9)M vs $(0.3)M; gross margin 37% vs 48% due to 70% retroactive ThyGeNEXT price cut.","Cash balance fell to $1.9M at June 30 from $3.8M year ago; DSO improved 15% to 59 days.","Launched Point2Glucose test; YTD net loss improved $1.5M to $(6.1)M; new thyroid data published."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":4410000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364463,"accession_number":"0001493152-22-013852","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Q1 revenue up 6% to $10.4M; net loss narrows to $2.2M from $4.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $10.4M, +6% YoY; net loss improved to $2.2M from $4.2M in Q1 2021.","Gross margin 48% vs 46% prior year; DSO decreased 27% to 63 days.","Adjusted EBITDA loss $0.9M, flat YoY; cash $2.9M at March 31, 2022.","Entered $2M convertible note agreement with BroadOak Fund V, L.P. on May 5, 2022 for working capital.","Collaboration with Twist Bioscience and Miroculus to automate NGS library prep using digital microfluidics."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":2454000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364462,"accession_number":"0001493152-22-012703","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Interpace Biosciences issues $2M convertible note to BroadOak; conversion tied to PIPE of >=$10M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$2M principal, 9% annual interest, unsecured, interest-only until Aug 5, 2022 maturity date.","Converts into common stock automatically if PIPE closing of at least $10M net proceeds occurs by maturity.","If PIPE not closed by Aug 5, 2022, converts into additional term loan under existing BroadOak subordinated facility.","Comerica Bank consented; note is subordinated to Comerica's senior secured debt.","Proceeds used for general corporate purposes and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":364461,"accession_number":"0001493152-22-009920","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2022-04-14T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Interpace Biosciences dismisses BDO, hires EisnerAmper as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated BDO USA, LLP as independent auditor effective April 13, 2022.","Appointed EisnerAmper LLP as new independent registered public accounting firm.","BDO's audit reports for 2021 and 2020 included a going concern explanatory paragraph.","Material weakness in internal controls related to asset impairment was reported.","No disagreements with BDO on accounting principles or procedures were noted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384162,"accession_number":"0001493152-22-008503","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2022-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace 2021 rev $41.3M (+28%), net loss improves to -$14.9M; CMS reversal on thyroid tests","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2021 net revenue $41.3M, up 28% YoY; Q4 revenue $10.9M, up 13% YoY.","Net loss improved to $(14.9)M from $(26.5)M; Adjusted EBITDA $(5.1)M vs $(15.4)M.","Cash collections $43.1M, up 31%, outpacing revenue; DSO decreased 40% to 54 days.","CMS retroactively reversed Jan 2022 billing policy for ThyGeNEXT/ThyraMIR; cash collections may be delayed.","Appointed Dr. Vijay Aggarwal to board, replacing Eric B. Lev, effective Feb 1, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":2454000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384161,"accession_number":"0001493152-22-002608","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2022-01-31T23:59:59+00:00","items":["1.02","8.01","9.01"],"status":"ready","headline":"Interpace terminates rights offering due to adverse CMS policy change for thyroid tests","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Terminated rights offering and standby purchase agreement with 3K Limited Partnership effective January 28, 2022.","CMS issued new billing policy: no longer reimburses ThyGeNEXT and ThyraMIR tests when billed together for same beneficiary on same date.","Company evaluating potential financial impact and preparing an appeal; seeking alternative financing sources.","CEO stated rights offering termination driven by likely adverse impact of CMS policy change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":384160,"accession_number":"0001493152-22-002401","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2022-01-27T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Interpace appoints Vijay Aggarwal to Board, replacing Eric Lev effective Feb 1, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric B. Lev resigns as director effective Feb 1, 2022; no disagreement with the Company.","Vijay Aggarwal appointed to Board effective Feb 1, 2022 as Class I director.","Aggarwal will Chair Regulatory Compliance Committee and serve on Nominating & Corporate Governance Committee.","Compensation: $50k annual director fee ($40k base + $10k committee chair) plus option for 28k shares.","Aggarwal has 30+ years in diagnostics/pharma; previously CEO of Vaxigenix, President of Aureon Labs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402002,"accession_number":"0001493152-21-027860","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Q3 revenue $9.5M, net loss $3.6M; new $7.5M facility, $8M term loan, $30M rights offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $9.5M (+15% YoY); loss from continuing ops $(3.5)M vs $(6.2)M; adjusted EBITDA $(1.8)M vs $(2.9)M.","Cash collections $10.4M (2nd consecutive record quarter); DSO down 48% YoY to 59 days; cash $3.2M at Sep 30.","Entered $7.5M Comerica revolver (matures Sep 2023) and $8M BroadOak term loan to repay private equity bridge loans.","Proposed $30M rights offering (backstopped by 3K Limited Partnership) to fund growth; goal $100M revenue run rate by 2023.","Expanded payor contracts: 54 commercial payors for thyroid tests; two new patents granted for ThyraMIR and PancraGEN technologies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":30461000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402001,"accession_number":"0001493152-21-027728","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Interpace Biosciences ratifies BDO USA as auditor; 10.9M votes for, 12.8K against","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ratified BDO USA, LLP as independent registered public accounting firm for FY ending December 31, 2021.","Vote results: 10,941,264 for, 12,769 against, 31,780 abstain.","Over 99.9% of votes cast in favor of ratification.","No other proposals were considered at the 2021 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":402000,"accession_number":"0001493152-21-027037","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Interpace enters $8M term loan with BroadOak at 9% to repay private equity loans","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$8M term loan from BroadOak at 9% interest, matures Oct 2024 or change-of-control.","Proceeds used to repay $4.5M Ampersand and $3M 1315 Capital promissory notes plus interest.","Loan includes 3% origination fee and terminal payment of 15%-30% of original principal.","Subordinate to Comerica's $7.5M revolving facility; secured by substantially all assets.","Company believes new debt improves liquidity and operating flexibility without dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401999,"accession_number":"0001493152-21-025744","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2021-10-19T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Interpace Biosciences enters $7.5M revolving credit facility with Comerica Bank","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Credit facility of up to $7.5M, matures September 30, 2023, secured by substantially all assets.","Advances based on 80% of eligible accounts receivable plus $2M non-formula availability stepping down $250K/quarter.","Interest rate equals prime plus 0.50% (prime is greater of Comerica's rate or daily LIBOR + 2.5%).","Existing $7.5M bridge loans from private equity investors subordinated to Comerica's first-priority lien.","Proceeds for working capital and general corporate purposes; unused facility fee of 0.25% per annum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401998,"accession_number":"0001493152-21-024381","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2021-10-01T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Interpace Biosciences extends maturity of $7.5M in secured notes to October 31, 2021","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Ampersand Note principal $4.5M, 1315 Capital Note $3.0M; total $7.5M in secured debt.","Maturity date extended one month from September 30, 2021 to October 31, 2021.","This is the fourth amendment to each note; terms otherwise unchanged.","Security agreement remains in full force and effect.","Noteholders are related parties holding convertible preferred shares (39% and 26% fully diluted combined)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420922,"accession_number":"0001493152-21-021692","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2021-08-31T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Interpace extends maturity on $7.5M notes from Ampersand and 1315 Capital to Sep 30, 2021","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity of $4.5M Ampersand Note and $3.0M 1315 Capital Note extended to September 30, 2021.","Third amendments executed August 31, 2021; all other terms unchanged.","Notes held by related parties that collectively own ~65.3% of common stock on as-converted basis.","Security Agreement remains in full force and effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420921,"accession_number":"0001493152-21-019196","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2021-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Q2 revenue $11.2M (+105% YoY); gross margin 48% vs 29%, adj EBITDA loss narrows to $0.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $11.2M (+105% vs Q2 2020); six-month revenue $21.0M (+45% YoY).","Gross profit margin 48% (Q2 2020: 29%); loss from continuing ops improved to $3.4M from $5.5M.","Adjusted EBITDA $(0.3)M vs $(4.2)M in prior year; cash collections hit $11.5M in Q2, DSO down 32%.","Cash balance rose to $4.0M at July 31 from $2.8M at Dec 31, 2020; on track for >35% FY revenue growth.","New PLA code 0245U for ThyGeNEXT at $2,919; eviCore coverage for ThyGeNEXT/ThyraMIR effective July 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":20989000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-08-10T23:59:59+00:00|420921"}